Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
5.630
+0.100 (+1.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
May 06, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
Myriad Genetics's Earnings: A Preview
May 05, 2025
Via
Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings
May 05, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
3 Unprofitable Stocks Walking a Fine Line
May 02, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via
StockStory
Analyst Expectations For Myriad Genetics's Future
March 03, 2025
Via
Benzinga
1 Unprofitable Stock to Target This Week and 2 to Be Wary Of
May 01, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via
StockStory
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
April 30, 2025
More than half say genetic testing for mental health medications could reduce concerns
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
Management will participate in two upcoming investor healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
April 25, 2025
Podium presentation showcases the clinical application of Precise™ MRD
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Healthcare Stocks That Concern Us
April 25, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...
Via
StockStory
Topics
Stocks
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
April 21, 2025
Study published in the Journal of Clinical Psychopharmacology
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Demystifying Myriad Genetics: Insights From 10 Analyst Reviews
April 17, 2025
Via
Benzinga
Myriad Genetics Announces Inducement Awards
April 08, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
April 07, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
10 Analysts Assess Myriad Genetics: What You Need To Know
April 01, 2025
Via
Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
April 01, 2025
Via
Benzinga
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
April 01, 2025
Via
Benzinga
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
March 20, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
March 19, 2025
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.
Via
StockStory
Topics
Artificial Intelligence
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
March 17, 2025
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 per share. This might have investors contemplating their next move.
Via
StockStory
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
March 12, 2025
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.
Via
Benzinga
Why Are Myriad Genetics (MYGN) Shares Soaring Today
March 12, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook...
Via
StockStory
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
March 12, 2025
Via
Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
March 11, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...
Via
StockStory
Topics
Artificial Intelligence
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
February 25, 2025
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO.
Via
Benzinga
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
February 27, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why Myriad Genetics (MYGN) Shares Are Plunging Today
February 25, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025...
Via
StockStory
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
February 25, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.